ABOUT
Who is GAH
Golden Age Health (GAH) is a pharmaceutical platform specializing in rare and specialty diseases, creating a vital two-way bridge for innovation. We connect the world's most advanced therapies with patients in China, while simultaneously sourcing high-potential assets from China's maturing biotech ecosystem for global development and commercialization.
Our leadership team, comprised of seasoned global pharma executives including the former CEO of Biogen and the architects behind China's most successful rare disease launch (Spinraza), possesses the deep expertise needed to navigate complex business and cultural landscapes. We excel at bridging the gap between brilliant scientist-founders and global commercial success.
We offer flexible, end-to-end partnership models that cover the full commercialization spectrum, from regulatory strategy and market access to patient engagement and real-world evidence generation. Our mission is to accelerate patient access to medical breakthroughs by cutting time-to-market, de-risking launches for our partners, and creating sustainable value for payers and investors worldwide.
“My decades of launching breakthrough therapies —from Spinraza® to Keytruda® — have taught me a simple truth: science only fulfils its promise when patients can reach it. Golden Age Health exists to collapse that distance. Together with our partners we will turn access from a slogan into a measurable outcome—months, not years — for every family we serve.”
— Michel Vounatsos, Co-founder & Executive Chairman
RARE DISEASES
Rare Diseases In Numbers
Rare diseases are distinct from other diseases and characterized by high unmet need from a small patient pools. We are here to close the gap in under-served markets.
of rare diseases are life threatening. High unmet need and debilitating
Source: Rare Disease Int'l
85%
rare diseases identified worldwide. Only 5% have an approved treatment
Source: IQVIA
7'000
people affected globally, 3x more than all cancers combined.
Source: IQVIA
400m
rare disease treatments available in China vs Western Markets
Source: ISPOR
1 of 5
TEAM
Meet our team
Team led by former CEO of Biogen and regional president of MSD who respectively led hallmark Spinraza® and Keytruda® launches. We bring cross-functional depth in regulatory, market-access, real-world evidence combined with local presence in China. With 25+ rare and specialty disease launches in our combined careers, we have cut time-to-patient by up to 40% in underserved regions.
Michel Vounatsos
Co-founder & Executive Chairman
Former CEO of Biogen
Yossi BenAmram
Co-founder & Chief Strategy Officer
Former President Europe, MEA, Russia at MSD
Chao (Brook) Wu
CEO China
20 years pharma experience at MSD, Pfizer, Sanofi, etc.
Reda Rebib
Business development & Middle-East Operations
Former healthcare investor at EQT Partners
Jingyan Song
Medical Marketing
China
Leling Han
Medical Science Liaison
China
Yanmei Sun
Medical Science Liaison
China
Judy Wang
Senior Consultant, PR & Patient Advocacy
China
Yacine Hadjiat
Affiliated Regional Partners
Middle-East & Africa
Murali Parthasarathy
Affiliated Regional Partners
US & India
Jose Bastos
Affiliated Regional Partners
Latin America
APPROACH
How we work
Partnering with Golden Age Health means benefiting from proven expertise in launching rare and specialty disease treatments, especially in complex markets like China and Asia. Our partnerships are built on transparency, shared success metrics, and decades of operational know-how. We prioritize solving real patient journey challenges, ensuring accessible and affordable therapies tailored to unmet medical needs. Crucially, our team on the ground in China is also best positioned to identify the country's most promising innovations and guide their journey to the global stage. Expect a focused, innovative partner dedicated to commercializing rare and specialty disease solutions where they matter most. We welcome collaboration with innovators ready to expand their reach or bring their science to patients faster.
OUR EDGE
What sets us apart
01
Proven Rare Disease Launch Experience
Our leadership team has executed the most successful rare disease launches in China and Asia for landmark therapies including Spinraza® and Keytruda®.
02
Data-Driven, End-to-End Commercialization
We own the entire value chain, from dossier preparation to supply-chain management. Our execution is powered by real-world data and AI to drive precise patient-finding, omnichannel engagement, and value-based market access.
03
Mastery of the China Commercialization Playbook
We leverage a proven playbook for success in China's unique ecosystem, fully utilizing innovative pathways like the Hainan Medical Pilot Zone or Beijing Rare Disease Tianzhu Zone to accelerate patient access and navigate market complexities.
04
Bridging Chinese Innovation to the Global Stage
Our on-the-ground presence allows us to identify and partner with China's most promising biotechs, bridging their innovative assets to international markets for global development and success.
05
Flexible deal structures
Up-front + milestone, distribution & promotion, profit-share, or JV - our models fit partners of every size.
PRODUCTS
Our portfolio
Raxone
Supporting Chiesi Farmaceutici to expand Raxone access to China
LX101
Innostellar's Gene therapy for inherited retinal dystrophies (IRD) due to RPE65 gene mutation
Your Product?
NEWS
News and Press releases
Golden Age Health and Innostellar Biotherapeutics Sign Exclusive 10-Year Collaboration to Accelerate LX-101 Gene Therapy for Inherited Retinal Dystrophies due to RPE 65 gene mutation in Mainland China
July 14, 2025
Welcoming three outstanding professionals to the GAH family; Jingyan SONG, Yanmei SUN & Leling HAN
July 9, 2025
Golden Age Health (GAH) to participate in the JPM Healthcare Conference in San Francisco, January 8-11, 2024
January 8, 2024